Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation

Abstract

Controlling blood pressure is a global health priority; single-pill antihypertensive combinations may improve adherence, persistence, and outcomes. Areas covered: A novel combination of perindopril arginine and amlodipine besylate was recently approved. A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension. Dose-dependent hyperkalemia, impairment of renal function (especially in renovascular hypertension), angioedema, and teratogenicity were derived from experience with other ACE-inhibitors. Expert opinion: Substantial clinical trial experience with amlodipine or perindopril suggests that these two agents effectively lower blood pressure, and can reduce the risk of major adverse cardiovascular events, as in the Anglo-Scandinavian Cardiac Outcomes Trial. The incidence of adverse effects reported in clinical trials is lower than expected, likely due to exclusion of subjects previously exposed to its components; the nature of open-label, uncontrolled observational studies; and difficulty in recognizing and measuring cough and pedal edema. This new formulation of perindopril arginine protects its ethyl ester, without requiring physical separation from amlodipine in a single tablet, and is less hygroscopic than perindopril erbumine. These and other attributes may make this combination an attractive addition to the antihypertensive armamentarium.

Ion Channel Expression in Human Melanoma Samples: In Silico Identification and Experimental Validation of Molecular Targets

“…Given the exceptional role of ion channels in controlling almost any cellular function, drugs targeting ion channels may cover a market of several billion USD [2]. Thus, it is no surprise the large interest pharmaceutical companies give to ion channels as molecular targets in many different pathological conditions, such as pain relief [3], cardiovascular diseases [4,5,6], diabetes [7], infectious diseases such as Hepatitis C virus [8] and influenza virus [9], CNS diseases [10,11,12,13], and cystic fibrosis [14,15]. Increasing interest is currently given to ion channels in cancers since they have been indicated as potential drug targets in many cancer conditions [16,17,18].…”

Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

“…In the present study, we investigated the pharmacological outcome of low-dose levamlodipine besylate on hypoperfusion-induced VaD. Levamlodipine was often used at the dose of 0.05 mg/kg on patients in clinical research 18 . According to the guide for dose conversion between animals and human, relevant papers choose the dosage of 1 mg/kg in rats 19 .…”

A Case of Secondary Hypersomnia Associated with Amlodipine

“…Somnolans ise dozdan bağımsız olarak %1,4 olarak görülmektedir. Ayrıca somnolans kadınlarda erkeklerden daha fazla olarak görülmektedir (8,9). Somnolans ve hipersomni birbirinden ayrı durumlardır.…”